Treatment discontinuation rates due to lack of efficacy through 1 year of maintenance treatment with vedolizumab or subcutaneous infliximab in patients with inflammatory bowel disease: a systematic literature review and meta-analysis.

Date publication

octobre 2025

Journal

Therapeutic advances in gastroenterology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Ferrante M, Peyrin-Biroulet L, Arkkila P, Armuzzi A, Colombel JF, Danese S, Faggiani R, Guardiola J, Hanauer SB, Jahnsen J, Reinisch W, Roblin X, Smith PJ, Sang Kwon T, Kim S, Nam K, Atreya R

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41079427

Résumé

Infliximab (IFX) and vedolizumab (VDZ), frequently used biologics in inflammatory bowel disease (IBD), are available as intravenous (IV) and subcutaneous (SC) formulations; however, comparative data are limited.

Mots clés

Crohn’s disease, alpha 4 beta 7 integrin inhibitor, treatment discontinuation, tumor necrosis factor inhibitor, ulcerative colitis

Référence

Therap Adv Gastroenterol. 2025 10 8;18:17562848251383767